Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulagtima versus Trulicity in type 2 diabetes
IRCT20101012004920N12Phase 3Completed
- Sponsor
- Artiman Pharmed Alborz
- Start
- Oct 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of dulaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Artiman Pharmed Alborz. Primary endpoint: Change in glycosylated hemoglobin (HbA1c). Started Oct 2024; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20101012004920N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20101012004920N12.